Medical imaging software developer MIM Software has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for post-treatment dosimetry of yttrium-90 (Y-90) microspheres.
Yttrium-90 microspheres deliver local radiation as permanent brachytherapy implants to liver tumors. Currently, PET or SPECT images are obtained after treatment to verify the microsphere distribution, but now absorbed dose from the Y-90 microspheres can be calculated on a voxel-by-voxel basis using the PET or SPECT images, according to the firm.
MIM SurePlan LiverY90 provides tools for liver and tumor segmentation, deformable registration, and patient-specific dose calculation on Y-90 PET and Bremsstrahlung SPECT images after permanent Y-90 microsphere implant administration.
Three methods are available for dose calculation: Local Deposition Model, Local Deposition Model with scaling for known injected activity, and the Voxel S Value approach based on the schema in the Medical Internal Radiation Dose Committee (MIRD) pamphlet No. 17: The Dosimetry of Nonuniform Activity Distributions -- Radionuclude S Values at the Voxel Level. All three methods are available for PET, while only the Local Deposition Model with scaling for known activity is available for SPECT images that are not in Becquerel per milliliter (Bq/mL), the firm said.
